News

PharmExec9h
FDA Approves Azurity Pharmaceuticals’ Xifyrm for Moderate-to-Severe Pain Management
Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...
PharmExec11h
FDA Grants Priority Review to Jazz Pharmaceuticals’ Zepzelca in Combination with Tecentriq for Extensive-Stage Small Cell Lung Cancer
Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...
PharmExec11h
Eli Lilly’s Novel Investigational Antibody Drug Conjugate Demonstrates High Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer
Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...
PharmExec17h
Executive Orders and Drug Pricing: Constitutional Limits on the Most Favored Nation Model
Ron Lanton, Partner, Lanton Law, discusses the constitutional and statutory challenges facing the President’s use of executive orders to implement international drug pricing models such as the Most ...
PharmExec18h
Lung Cancer Research Foundation Announces Expansion of its Research Advocate Group
The Lung Cancer Research Foundation is expanding its research advocate groups. The group is made up of lung cancer patients ...
PharmExec18h
New Study Shows Test Can Predict Patient Response to Anti-Obesity Medications
Phenomix Sciences published the results of a study conducted in partnership with the Mayo Clinic that tested the ...
PharmExec18h
The Antibody-Drug Conjugate Renaissance
Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...